Vancouver, BC-based AbCellera (Nasdaq: ABCL) and Atlas Venture, a Cambridge, MA-based biotech venture capital firm, announced a multi-target partnership to discover therapeutic antibodies for up to three drug targets that can be developed and commercialized by a stealth-stage Atlas-backed company.
Under the terms of the agreement, Atlas’ portfolio company will have the right to develop and commercialize therapeutic antibodies resulting from the collaboration. AbCellera will receive research payments and will be eligible to receive clinical and commercial milestone payments and royalties on net sales of products.
The collaboration leverages Atlas’ proven track record in forming innovative biotechnology companies and AbCellera’s ability to quickly deliver lead drug candidates to bring transformational new medicines to patients faster.
Led by Carl Hansen, Ph.D., CEO and President, AbCellera is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease. The company partners with drug developers of all sizes, from large pharmaceutical to small biotechnology companies, empowering them to move quickly, reduce cost, and tackle the toughest problems in drug development.
FinSMEs
11/08/2022